Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
J Clin Microbiol. 2018 Aug 27;56(9). doi: 10.1128/JCM.00472-18. Print 2018 Sep.
The purpose of this study was to develop and optimize different processing, extraction, amplification, and sequencing methods for metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) specimens. We applied mNGS to 10 CSF samples with known standard-of-care testing (SoC) results (8 positive and 2 negative). Each sample was subjected to nine different methods by varying the sample processing protocols (supernatant, pellet, neat CSF), sample pretreatment (with or without bead beating), and the requirement of nucleic acid amplification steps using DNA sequencing (DNASeq) (with or without whole-genome amplification [WGA]) and RNA sequencing (RNASeq) methods. Negative extraction controls (NECs) were used for each method variation (4/CSF sample). Host depletion (HD) was performed on a subset of samples. We correctly determined the pathogen in 7 of 8 positive samples by mNGS compared to SoC. The two negative samples were correctly interpreted as negative. The processing protocol applied to neat CSF specimens was found to be the most successful technique for all pathogen types. While bead beating introduced bias, we found it increased the detection yield of certain organism groups. WGA prior to DNASeq was beneficial for defining pathogens at the positive threshold, and a combined DNA and RNA approach yielded results with a higher confidence when detected by both methods. HD was required for detection of a low-level-positive enterovirus sample. We demonstrate that NECs are required for interpretation of these complex results and that it is important to understand the common contaminants introduced during mNGS. Optimizing mNGS requires the use of a combination of techniques to achieve the most sensitive, agnostic approach that nonetheless may be less sensitive than SoC tools.
本研究旨在开发和优化用于脑脊髓液(CSF)标本的宏基因组下一代测序(mNGS)的不同处理、提取、扩增和测序方法。我们将 mNGS 应用于 10 份具有已知标准护理检测(SoC)结果的 CSF 样本(8 份阳性和 2 份阴性)。每个样本通过改变样品处理方案(上清液、沉淀、纯 CSF)、样品预处理(是否有珠磨)以及使用 DNA 测序(DNASeq)(是否有全基因组扩增 [WGA])和 RNA 测序(RNASeq)方法的核酸扩增步骤的要求,应用了 9 种不同的方法。每种方法变化(每份 CSF 样本 4 个)都使用阴性提取对照(NEC)。对一部分样本进行宿主耗竭(HD)处理。与 SoC 相比,我们通过 mNGS 在 8 个阳性样本中的 7 个中正确确定了病原体。两个阴性样本被正确解释为阴性。我们发现,对于所有病原体类型,应用于纯 CSF 标本的处理方案是最成功的技术。虽然珠磨会引入偏差,但我们发现它增加了某些生物体组的检测产量。在 DNASeq 之前进行 WGA 有利于在阳性阈值下定义病原体,并且当两种方法都检测到时,组合 DNA 和 RNA 方法的结果具有更高的置信度。HD 是检测低水平阳性肠道病毒样本所必需的。我们证明,对于这些复杂结果的解释,需要使用 NEC,并且了解在 mNGS 过程中引入的常见污染物非常重要。优化 mNGS 需要结合使用多种技术,以实现最敏感、无偏见的方法,但该方法的敏感性可能不如 SoC 工具。